Guardant Health Inc (GH)

NASDAQ
105.06
+5.62(+5.65%)
After Hours
105.06
0.00(0.00%)
- Real-time Data
  • Volume:
    1,647,337
  • Bid/Ask:
    105.06/107.00
  • Day's Range:
    99.44 - 106.91

GH Overview

Prev. Close
99.44
Day's Range
99.44-106.91
Revenue
323.66M
Open
100.09
52 wk Range
96.66-181.07
EPS
-3.77
Volume
1,647,337
Market Cap
10.07B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
918,466
P/E Ratio
-
Beta
-
1-Year Change
-1.54%
Shares Outstanding
101,298,669
Next Earnings Date
Nov 04, 2021
What is your sentiment on Guardant Health Inc?
or
Market is currently closed. Voting is open during market hours.

Guardant Health Inc News

Guardant Health Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyBuySellNeutral
Technical IndicatorsNeutralStrong SellStrong BuyStrong SellSell
SummaryNeutralNeutralStrong BuyStrong SellNeutral

Guardant Health Inc Company Profile

Guardant Health Inc Company Profile

Employees
864

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.

Read More
  • I am so imptient to see Q3 figures with FDA approval on blood test and covid test 🚀🚀
    0
    • doing well...
      0
      • one of the only stocks to actually have gains......I missed my chance
        0
        • I was right, inept people are written reccomendations for money given by such sh... company like GH.
          3
          • I followed zacks.com reccommendations but simply; worth for nothing (so many others)!
            1
            • Hope GH will fall to 30 lol
              0
              • this is a tremendous company: it was though impossible to buy at the levels it reached: now it is starting to have some serious upside.
                1
                • up 20% as I go to buy this week. bad timing but good for shareholders
                  0
                  • who's still confident? And why?
                    0
                    • Note to self, "this stock is strong and healthy, but it has a bi-polar disorder."
                      0
                      • So true but i think it will show more great manic lifts that exceed any depressing slumps in the future
                        2
                      • Lmao
                        0
                    • This looks promising
                      0
                      • Ipo :=)
                        0
                        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.